Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-5491|32|3|305-313

ISSN： 0742-3071

Source： DIABETIC MEDICINE, Vol.32, Iss.3, 2015-03, pp. : 305-313

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predicting risk of bladder cancer in the UK

By Coupland Carol   Hippisley-Cox Julia  

British Journal of General Practice, Vol. 62, Iss. 604, 2012-11 ,pp. : 570-571

Royal College of General Practitioners

Access to resources Recommend Favorite

Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone

By  

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 234-244

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?

By  

Current Drug Safety, Vol. 8, Iss. 5, 2013-11 ,pp. : 364-370

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic susceptibility to bladder cancer risk and outcome

By Gu Jian   Wu Xifeng  

Personalized Medicine, Vol. 8, Iss. 3, 2011-05 ,pp. : 365-374

Future Medicine

Access to resources Recommend Favorite

A Meta-Analysis of Tea Consumption and the Risk of Bladder Cancer

By  

Urologia Internationalis, Vol. 90, Iss. 1, 2012-10 ,pp. : 10-16

Karger

Access to resources Recommend Favorite